Get the Stockscreener App
0.1849
2.01%
-0.0038
Catheter Precision Inc. stock is traded at $0.1849, with a volume of 286.26K.
It is down -2.01% in the last 24 hours and down -34.34% over the past month.
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
See More
Previous Close:
$0.1887
Open:
$0.183
24h Volume:
286.26K
Relative Volume:
0.58
Market Cap:
$2.04M
Revenue:
$24,000
Net Income/Loss:
$-78.06M
P/E Ratio:
-0.00638
EPS:
-28.9956
Net Cash Flow:
$-21.81M
1W Performance:
-22.93%
1M Performance:
-34.34%
6M Performance:
-56.94%
1Y Performance:
-96.32%
1-Day Range:
$0.1775
$0.1892
1-Week Range:
$0.1648
$0.24
52-Week Range:
$0.1648
$8.40
Catheter Precision Inc. Stock (VTAK) Company Profile
Name
Catheter Precision Inc.
Sector
Industry
Phone
973 691 2000
Address
1670 Highway 160 West, Suite 205, Fort Mill
Compare VTAK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTAK
Catheter Precision Inc.
|
0.1849 | 2.64M | 24,000 | -78.06M | -21.81M | -29.00 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Catheter Precision Inc. Stock (VTAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-02-18 | Initiated | Maxim Group | Buy |
Catheter Precision Inc. Stock (VTAK) Latest News
Catheter Precision, Inc. Receives Ce Mark for LockeT - marketscreener.com
Catheter Precision (VTAK) Achieves CE Mark Approval for LockeT D - GuruFocus
Catheter Precision Receives CE Mark Approval for LockeT Vascular Closure Device - marketscreener.com
Catheter Precision, Inc. Receives CE Mark for LockeT | VTAK Stock News - GuruFocus
Catheter Precision, Inc. Receives CE Mark Approval for LockeT, Expanding Market Opportunities in Europe - Nasdaq
Catheter Precision, Inc. Receives CE Mark for LockeT - The Manila Times
Catheter Precision Unlocks $4.3B European Market with CE Mark: First Orders Already Flowing - Stock Titan
Why Intuit Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
Why Urban Outfitters Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Catheter Precision Inc Files For Resale Of Up To 12.9 Million Shares Of Common Stock By The Selling StockholdersSEC Filing - marketscreener.com
Catheter Precision Enters Market Offering Agreement - MSN
Catheter Precision Enters At Market Offering Agreement With Ladenburg Thalmann & Co. IncSEC Filing - marketscreener.com
QHSLab Signals Debt Restructuring - citybiz
QHSLab, Inc. Signals Strategic Debt Restructuring to Strengthen Balance Sheet and Drive Growth - TradingView
Breakthrough Patent: How Autonomix Medical's New Nerve-Mapping Tech Could Transform Pain Treatment - Stock Titan
Catheter Precision revenue increases 74% to USD 143K in Q1 2025 - Medical Buyer
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results | VTAK Stock News - GuruFocus
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results - The Manila Times
Catheter Precision Q1 Revenue Surges 74% as Clinical Studies Show 94% Accuracy in Heart Procedures - Stock Titan
Catheter Precision Enters Securities Purchase Agreement - TipRanks
Catheter Precision, Inc. Announces $1.5 Million Private Placemen - GuruFocus
Catheter Precision (VTAK) Secures $1.5M Through Private Equity F - GuruFocus
Interim Financial Results - The Manila Times
Catheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic Alliance | VTAK Stock News - GuruFocus
Catheter Precision (VTAK) Secures $1.5M Through Private Equity Financing | VTAK Stock News - GuruFocus
Catheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic Alliance - GlobeNewswire
Catheter Precision Finalizes Strategic Cardiac Acquisition - TipRanks
Catheter Precision completes acquisition of Cardionomic heart failure assets - TipRanks
Catheter Precision (VTAK) Subsidiary Acquires Cardionomic's Hear - GuruFocus
Catheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure Assets - The Manila Times
Medical Breakthrough: Catheter Precision Takes Over Million-Patient Heart Failure Treatment Innovation - Stock Titan
Catheter Precision (VTAK) Reveals Enhanced Clinical Data on VIVO System | VTAK Stock News - GuruFocus
New Clinical Data Presented about VIVO at the 46th Annual Heart Rhythm Association Conference - The Manila Times
Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society - The Manila Times
Catheter Precision Inc [VTAK] Director makes an insider purchase of 3 shares worth 1.0. - knoxdaily.com
Catheter Precision to Attend and Participate in the 46th Heart R - GuruFocus
Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society | VTAK Stock News - GuruFocus
Breakthrough Cardiac Study: Catheter Precision's VIVO System Achieves 94% Accuracy in European Multi-Center Trial - Stock Titan
Catheter Precision to acquire late-stage heart failure treatment assets in development - MSN
Analytical Lens: Exploring Catheter Precision Inc (VTAK)’s Financial Story Through Ratios - DWinneX
Catheter Precision Inc (VTAK) Stock: A Year of Highs and Lows in the Market - investchronicle.com
Can Catheter Precision Inc (VTAK) meet market expectations this quarter? - uspostnews.com
How analysts predict Five9 Inc (FIVN) will perform this quarter? - uspostnews.com
Catheter Precision (VTAK) Acquires Assets for Cardiac Technology Expansion | VTAK Stock News - GuruFocus
Catheter Precision to acquire assets of Cardionomic related to CPNS system - TipRanks
Catheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart Failure - The Manila Times
Catheter Precision To Acquire Assets In Development For Late-Stage Treatment For Acute Decompensated Heart Failure - marketscreener.com
Breakthrough Heart Failure Treatment Tech With 1M Patient Potential Acquired: Early Clinical Success Revealed - Stock Titan
Catheter Precision Inc. Stock (VTAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.38%
Cap:
|
Volume (24h):